CAJ | 학술논문

目的　131I标记人源抗HBsAg Fab经腹腔注射治疗荷人肝癌裸鼠移植瘤，与131I-S102比较，评价其作为肝癌放射免疫治疗(RIT)的可能性。方法　荷瘤裸鼠分为4组分别经腹腔注射不同放射剂量的131I-抗HBsAg Fab、131I-S102、131I-无关Fab及PBS。按一定时间间隔作组织分布和血液清除速率测定，继续观察4周，以外周血白细胞和血小板数量变化行毒性分析，计算各组肿瘤生长抑制率。结果　131I-抗HBsAg Fab被肿瘤区的摄取和在血液中清除速率均明显快于131I-S102，同等剂量下，前者抗肿瘤疗效略低，但血液毒性明显减轻。结论　人源抗HBsAg Fab具有良好的免疫结合活性，核素标记后用于RIT，能够被肿瘤快速摄取并在体内正常组织中快速清除，毒性减低，具有良好的抗肿瘤疗效，是原发性肝癌RIT的理想载体。
목적　131I표기인원항HBsAg Fab경복강주사치료하인간암라서이식류，여131I-S102비교，평개기작위간암방사면역치료(RIT)적가능성。방법　하류라서분위4조분별경복강주사불동방사제량적131I-항HBsAg Fab、131I-S102、131I-무관Fab급PBS。안일정시간간격작조직분포화혈액청제속솔측정，계속관찰4주，이외주혈백세포화혈소판수량변화행독성분석，계산각조종류생장억제솔。결과　131I-항HBsAg Fab피종류구적섭취화재혈액중청제속솔균명현쾌우131I-S102，동등제량하，전자항종류료효략저，단혈액독성명현감경。결론　인원항HBsAg Fab구유량호적면역결합활성，핵소표기후용우RIT，능구피종류쾌속섭취병재체내정상조직중쾌속청제，독성감저，구유량호적항종류료효，시원발성간암RIT적이상재체。
Objective　To explore the possibility of anti-HBsAg Fab as carrier of HCC radioimmunotherapy.Methods　The nude mice models with human hepatoma were injected with 131I-human anti-HBsAg Fab into the peritoneal cavity (i.p). Radioimmunoimage was taken at different intervals, and tissue distribution was measured. The tumor growth inhibition rate was determined by measurement of tumor volume. The radiotoxicity was evaluated by leukocyte and platelet counts monitored at weekly intervals. Results　Tumor uptake and the clearance of 131I-anti-HBsAg Fab in normal organs was faster than that of 131I-S102. The tumor growth inhibtion rate in 131I-anti-HBsAg Fab-IP mice was lower slightly than that in 131I-S102 groups, but the hematologic toxicity was significantly lower than that in the latter. Conclusion　The human anti-HBsAg Fab has a considerable targeting activity, and may be used as a novel humanized vector for targeting therapy of hepatoma.